Pharmafile Logo

MedTech specialist joins Research Partnership

June 21, 2022 | Medtech 

Janet Powers has joined the company as a Director in the MedTech division.

We are delighted to announce that Janet Powers has joined the company as a Director in the MedTech division. Based in the US, Janet has worked in healthcare her entire career and has over 21 years of experience in research and consulting. She brings strong MedTech experience to the team having worked with most of the top 25 firms in the industry.

Janet most recently served as Senior Vice President of Research at MedPanel overseeing all qualitative and quantitative projects, recruitment and panel development. Other previous roles include Director of Business Intelligence at Philips Healthcare and Vice President of Analysis at Eliza Corporation.

Head of the MedTech Division, Sabera Hyderally said of her appointment, “I am delighted to welcome Janet to the MedTech Division. She brings a wealth of experience, deep knowledge and fresh ideas and I’m excited to partner with a researcher of her calibre as we continue our tremendous growth globally.”

Speaking about the appointment, Co-CEO Mary Assimakopoulos said, “We are very pleased that Janet has chosen to join Research Partnership. She has previously worked with a range of MedTech clients and brings a great depth of experience to the team, which aims to stay at the forefront of best practice and innovation.”

Visit researchpartnership.com to find out more.

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Intelligent Commercialization™ across the pharma lifecycle

Pharma teams are under growing pressure to navigate launch complexity, identify risks earlier, and engage HCPs more effectively.

Four steps to a smarter congress strategy: A practical guidebook

This guidebook explores how Intelligent Congress helps pharma teams create more coordinated, measurable, and impactful congress strategies.

Infographic: Are data blind spots putting your launch at risk?

Commercial pharma launches depend on confident, evidence-led decisions. Yet many launch teams are still working with fragmented data spread across multiple systems, making it difficult to understand market readiness, prioritize…

Key takeaways from ASCO® 2026

Following ASCO® 2026, Inizio’s experts have shared their perspectives across three thought leadership articles, each exploring a different aspect of what this year’s congress revealed for pharmaceutical organisations. Together, they…

Webcast | Smarter science, sharper strategy: Expert perspectives from ASCO® 2026

Key insights from ASCO® 2026, including oncology trends, scientific highlights, and strategies for smarter congress engagement.

From activity to impact: 5 takeaways from MAPS Americas 2026

Across sessions, panels, and conversations on the ground in Denver, there was a noticeable shift in both mindset and momentum. Many of the themes discussed in previous years are now…

Inizio launches Intelligent Congress: Turning medical event investment into measurable impact

Inizio, the global commercialization partner to the health and life sciences industry, today announced the launch of Intelligent Congress – a connected, end-to-end solution designed to help pharma organizations maximize…

Inizio Unveils Next-Generation Hub Services at Asembia 2026, Setting a New Standard in Patient Access

Integrated capabilities combining advanced analytics, pharmacy, and specialized talent to improve access, affordability, and adherence

5 takeaways from Reuters’ Pharma USA 2026 – and what they mean for you

Pharma USA is North America’s largest cross-functional pharma event and Inizio was there to offer insights on patient engagement, accelerated product launches, and Intelligent Commercialization™. Now we’re back in the…

Precision Medical Affairs in Action: Using AI and Analytics to Elevate Strategy, Engagement, and Impact

Discover how AI, analytics and real-world data are reshaping Medical Affairs.